Latest News
-
Memory B cell marker predicts long-lived antibody response to flu vaccine
These effector memory B cells appear poised for a rapid serum antibody response upon secondary challenge one year later, and evidence shows that the cells in this subset differ from all previously described memory B cell subsets. -
UAB and Diamond Therapeutics, Inc., launch psilocybin clinical trial
The trial will evaluate the effects of low doses of psilocybin on combating demoralization in broader populations. -
All of Us Research Program launches new enrollment location in Dothan, Ala.
The All of Us Southern Network has enrolled more than 30,000 people. The new Dothan location will extend enrollment opportunities into the Wiregrass. -
UAB startup receives $2.5 million FastTrack Grant from the NIH
The grant validates the science of Alveolus Bio, and the funds will support development of first-of-its-kind inhaled biotherapeutics to treat chronic lung diseases. -
FDA mandate to limit acetaminophen in acetaminophen-opioid medications is associated with reduced serious liver injury
The federal mandate, which was announced in 2011 and implemented in 2014, limited acetaminophen to 325 milligrams per opioid-acetaminophen combination pill. Acetaminophen is toxic to livers at high doses. -
Could learning magic arts benefit adolescents with unilateral cerebral palsy?
The National Endowment for the Arts has awarded UAB Arts in Medicine a research grant to study whether magic arts training can help improve motor and social-emotional function.
